

# Infigratinib

Catalog No: tcsc0586



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg

**Size:** 1g

**Size:** 2g



## Specifications

**CAS No:**

872511-34-7

**Formula:**

$C_{26}H_{31}Cl_2N_7O_3$

**Pathway:**

Protein Tyrosine Kinase/RTK

**Target:**

FGFR

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 27 mg/mL (48.17 mM; Need ultrasonic and warming)

#### Alternative Names:

BGJ-398;NVP-BGJ398

#### Observed Molecular Weight:

560.48


### Product Description

Infigratinib (BGJ-398) is a potent inhibitor of the **FGFR** family with **IC<sub>50</sub>**s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.

IC50 & Target: IC50: 0.9 nM (FGFR1), 1.4 nM (FGFR2), 1 nM (FGFR3), 60 nM (FGFR4)<sup>[1]</sup>

**In Vitro:** Infigratinib (BGJ-398) inhibits FGFR1, FGFR2, and FGFR3 with IC<sub>50</sub>=~1 nM, FGFR3<sup>K650E</sup> with IC<sub>50</sub>=4.9 nM, and FGFR4 with IC<sub>50</sub>=60 nM. IC<sub>50</sub> values for all other kinases are in the μM range (FYN, LCK, YES, and ABL, IC<sub>50</sub>=1.9, 2.5, 1.1, and 2.3 μM, respectively) except for VEGFR2, KIT, and LYN, which are inhibited at submicromolar concentrations (IC<sub>50</sub>=0.18, 0.75, and 0.3 μM, respectively). Infigratinib (BGJ-398) inhibits the proliferation of the FGFR1-, FGFR2-, and FGFR3-dependent BaF3 cells with IC<sub>50</sub> values which are in the low nanomolar range and comparable to those observed for the inhibition of the receptors kinase activity in the enzymatic assay. For the remaining cells, all IC<sub>50</sub> values are greater than 1.5 μM except for VEGFR2 (IC<sub>50</sub> 1449 and 938 nM), for which there is at least a 400-fold selectivity versus FGFR1, FGFR2, and FGFR3<sup>[1]</sup>. Infigratinib (BGJ-398) (ranging between 1 nM and 10 μM) is potent at inhibiting cell growth of *FGFR2*-mutant endometrial cancer cells<sup>[2]</sup>.

**In Vivo:** Infigratinib (BGJ-398) is administered to athymic nude mice implanted subcutaneously with RT112/luc1 tumors: either as a 5 mg/kg intravenous bolus in NMP/PEG200 (1:9, v/v) or orally by gavage as a suspension in PEG300/D5W (2:1, v/v) at a 20 mg/kg dose. The relevant pharmacokinetic (PK) parameters indicate that the oral bioavailability of Infigratinib (BGJ-398) in this study is 32%. After intravenous dosing, Infigratinib (BGJ-398) shows a rapid distribution from the vascular compartment into the peripheral tissues, translating into a high volume of distribution (26 L/kg). The plasma clearance is high at 3.3 L/h/kg (61% of liver blood flow). The ratio of tumor to plasma after oral dosing based on AUC is determined to be 10<sup>[1]</sup>. Infigratinib (BGJ-398) (30 mg/kg) significantly inhibits the growth of *FGFR2*-mutated endometrial cancer xenograft models<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!